S100A4 and pulmonary fibrosis: Identifying potential biomarkers of targeted inhibition by MLN0128 will be important for designing clinical trials in pulmonary fibrosis patients- PAI-1, FN, and S100A4 are potential biomarkers since they are inhibited by MLN0128 in the bleomycin model (Figure S3).